- Home
- GOSS vs BUDA Comparison
GOSS vs BUDA Comparison
Compare GOSS & BUDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOSS | BUDA |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 101.2M | 119.0M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | GOSS | BUDA |
|---|---|---|
| Price | $0.40 | $10.25 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $4.19 | N/A |
| AVG Volume (30 Days) | ★ 26.2M | 17.0K |
| Earning Date | 03-17-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $48,471,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $203.01 | N/A |
| P/E Ratio | ★ N/A | $24.42 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.33 | $7.61 |
| 52 Week High | $3.87 | $10.69 |
Technical Indicators
Market Signals| Indicator | GOSS | BUDA |
|---|---|---|
| Relative Strength Index (RSI) | 23.42 | 51.30 |
| Support Level | $0.33 | $8.06 |
| Resistance Level | $0.60 | $10.55 |
| Average True Range (ATR) | 0.06 | 0.90 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 0.00 | 55.02 |
Price Performance
Historical ComparisonAbout GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About BUDA Buda Juice Inc. Common Stock
Buda Juice Inc operates in a competitive beverage industry, focused on fresh, cold-crafted juice production for business-to-business (B2B) distribution. The Company mostly utilizes third-party delivery systems and operates within the State of Texas serving large, national chain grocery stores. It is pioneering a new category in beverages-UltraFresh juice-offering cold-crafted citrus-based drinks that are never pasteurized, never HPP- processed, never UV- treated and always cold.